Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Apellis Pharmaceuticals, and BridgeBio Pharma. The word on The Street in general, suggests a Strong Buy analyst ...

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on November 4. Graig ...

Apellis Pharmaceuticals APLS is gearing up ... on the analyst ratings and average 1-year price targets of Amicus Therapeutics, Iovance Biotherapeutics and Rhythm Pharmaceuticals, three prominent ...

Dr Arshad Khanani reports on several compelling talks given at the neovascular AMD session at AAO 2024. Dr Barbara Blodi presented higher rates of macular atrophy in patients treated with anti ...

Verrica Pharmaceuticals (VRCA), 618% surge in interest Verona Pharma (VRNA), 439% surge in interest Journey Medical (DERM), 356% surge in interest Nektar Therapeutics (NKTR), 281% surge in ...

HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.66) EPS and FY2024 earnings at $1.04 EPS. Skip to main content Analyst Ratings ...

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago.

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast ...

The analysis below examines the analyst ratings and average 1-year price targets of Amicus Therapeutics, Rhythm Pharmaceuticals and Apellis Pharmaceuticals, three significant industry players ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) – HC Wainwright lifted their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued on Tuesday, November 5th.